Novitero

Next generation proactive cancer threatment by design of drugs bypassing resistance Cancer cells constantly undergo genomic changes (i.e. mutations), which allow them to escape from the body?s defense mechanisms and from already marketed targeted drugs, and enables them to continue to divide and spread. Novitero's innovation lies in predicting and smartly bypassing the potential future mutations that the cancer may adopt to resist therapies using unique computer-based technologies and algorithms. We design and develop new structurally adapted drugs to a-priory bypass these upcoming mutations, validate and outlicense these new mutation-bypassing drugs to pharmaceutical companies. The out-licensing at the early preclinical stage, subsequent to IP creation and experimental validation, leads to rapid value creation with markedly reduced risk. The company answers an immense and growing need of combating these resistances with the potential to provide enduring solution for many patients in various cancer types where current drugs fail.